Anaptysbio (ANAB) Appoints Daniel Faga to its Board

Go back to Anaptysbio (ANAB) Appoints Daniel Faga to its Board

AnaptysBio Announces Appointment of Daniel Faga to Board of Directors

November 29, 2021 4:06 PM EST

SAN DIEGO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced the appointment of Mr. Daniel Faga to the companys Board of Directors.

Dan has extensive corporate strategy, finance and public company leadership experience in building world-class biopharmaceutical companies, said Hamza Suria, president and chief executive officer of AnaptysBio. His unique strategic vision is an exciting addition to our Board of Directors and we look forward to having Dans... More